Sign in: Staff/Students
New analysis of plans to introduce a sugar labelling policy for packaged foods and beverages in the United States provides details of the potential health and economic impacts of the new label.
In the United States, the Food and Drug Administration’s (FDA) mandatory added sugar labelling policy for packaged foods and beverages is set to take effect between 2020 and 2021.
According to a new modelling study, led by researchers from the University of Liverpool and the Friedman School of Nutrition Science and Policy at Tufts University, the scheme could be a cost-effective way to generate important health gains and cost-savings for both the healthcare system and society in the U.S.
The analysis is the first to estimate the potential health and economic impacts of the new label.
In 2016, the FDA announced several mandatory changes to the Nutrition Facts label in order to provide consumers with enhanced nutritional information. Among the changes was adding the grams and percent Daily Value of added sugar content, which would help consumers limit calories from added sugar in accordance with the recommendations of the 2015-2020 Dietary Guidelines for Americans.
The study, published today in Circulation, estimates that the FDA’s added sugar label could prevent or postpone nearly 1 million cases of cardio metabolic disease, including heart disease, stroke and type 2 diabetes, over a 20-year period. When combined with possible industry reformulations to reduce added sugar content in packaged foods and beverages, the label could prevent or postpone nearly 3 million cases of cardiovascular disease and diabetes over the same time period. Cost-effectiveness of each scenario was evaluated from a healthcare perspective (accounting for policy costs and medical costs) and from a societal perspective (further accounting for informal care costs and lost productivity costs). Both scenarios were estimated to be cost-effective within five years and cost-saving within seven years.
Specifically, the analysis estimates that the added sugar label could:
• Prevent or postpone 354,400 cases of cardiovascular disease and 599,300 cases of diabetes;
• Gain 727,000 quality-adjusted life-years (QALYs); and
• Save $31 billion in net healthcare costs and $61.9 billion in societal costs. Policy costs were estimated to be $1.7 billion.
Taking into consideration possible reformulation by the food industry, the analysis yielded greater corresponding gains, estimating that the new label could:
• Prevent or postpone 708,800 cases of cardiovascular disease and 1.2 million cases of diabetes;
• Gain 1.3 million QALYs; and
• Save $57.6 billion in net healthcare costs and $113.2 billion in societal costs. Policy costs, including industry reformulation costs, were estimated to be $4.3 billion.
While some companies have begun listing added sugar content, the 2018 deadline for compliance has been extended to 2020 for large manufacturers and 2021 for small manufacturers.
The researchers note that Americans consume more than 15 percent of their total calories from added sugars and overconsumption of added sugars is linked to an increased risk of cardio metabolic diseases. These diseases pose large health and economic burdens for the society and the healthcare system. Food labelling could be an effective strategy to support informed consumer choice and reduce added sugar intake, while further stimulating industry reformulation, as supported by recent experience with trans-fat labelling in the U.S.
The researchers used a validated microsimulation model (IMPACT) to estimate the potential health impact, costs, and cost-effectiveness of the FDA’s added sugar label based on the two scenarios, which were compared with a “no intervention” baseline scenario over a 20-year timeframe (2018-2037). The model generated a sample representative of the U.S. adult population and utilized data from the two most recent National Health and Nutrition Examination Survey cycles (2011–2014), CDC Wonder, meta-analyses, and other validated sources.
The model evaluated health benefits and cost-savings from cardio metabolic health outcomes; increased healthcare costs from competing diseases could reduce cost-effectiveness, while other health benefits would further contribute to health gains and cost-savings.
Professor Martin O’Flaherty, co-senior author and professor in epidemiology at the University of Liverpool, said: “Informing consumers about what is in their sugary drinks, cakes, and sweets will help them decide what they want to eat for their health now and later. Full implementation of the label before 2021 could help maximize health and economic gains.”
Dr Renata Micha, the study’s co-senior and corresponding author and research associate professor at the Friedman School of Nutrition Science and Policy at Tufts University, said: “The added sugar label is an important policy step toward reducing consumption of foods and beverages with high added sugar contents, improving health, and lowering healthcare spending.
“These findings have important implications for individuals, policy makers and the food industry alike. Modest industry reformulation would be a powerful way to maximize potential benefits, highlighting industry’s critical role in being part of the solution.”
The study is part of the Food Policy Review and Intervention Cost-Effectiveness (Food-PRICE) research initiative, a National Institutes of Health-funded collaboration of researchers led at Tufts University working to identify nutrition strategies that can have the greatest impact on improving diet and health in the United States.
This study was supported by awards from the National Heart, Lung, and Blood Institute of the National Institutes of Health. Additional support was provided through a postdoctoral fellowship award from the American Heart Association.
The full study, entitled ‘Cost-Effectiveness of the US Food and Drug Administration Added Sugar Labeling Policy for Improving Diet and Health’, can be found here.
You must be logged in to post a comment.
All recent news
Extending Duo two-factor authentication (2FA) to Canvas
World AIDS Day: Are long-acting HIV therapies the future?
Get involved: Activities and events happening this week
New UK coronavirus measures introduced
Obituary: Dr Stephan Pfaffenzeller
Leading experts in the fields of pharmacology and advanced materials, Prof Andrew Owen and Prof Steve Rannard from @CELTLiverpool discuss their pioneering work into long-acting therapeutics for the treatment of HIV.
Full story ➡️ https://bit.ly/3G5Nc3s
Persistent poverty and/or persistent poor parental mental health affects over four in ten children in UK today, @LivUni-led analysis finds ➡️ https://bit.ly/3xButtM
£1.6m programme led by @MPUoL seeks to understand the very rare, but very serious, condition of blood clotting with low platelets in the general population, in #COVID19 infection & potentially following vaccination ➡️ https://bit.ly/3o5GtR1